Pallavi Parab

Pallavi Parab

Auto-generated profile, based on publicly available information

Pallavi Parab

Department of Medical Oncology, Tata Memorial Centre, Mumbai, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SGSudeep Gupta
Sudeep Gupta
NNNita Nair
Nita Nair
RHRohini W. Hawaldar
Rohini W. Hawaldar
SJShalaka Joshi
Shalaka Joshi
SGSeema Gulia
Seema Gulia
RBRajendra A. Badwe
Rajendra A. Badwe
PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m 2 ) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.

14 February 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
NGNilesh Laxman Gardi
Nilesh Laxman Gardi
RCRohan Chaubal
Rohan Chaubal
PPPallavi Parab
Pallavi Parab
SPSunil Pachakar
Sunil Pachakar
SKSuyash Sureshchandra Kulkarni
Suyash Sureshchandra Kulkarni
SGSudeep Gupta
Sudeep Gupta
We report a deep next-generation sequencing analysis of 13 sequentially obtained tumor samples, eight sequentially obtained circulating tumor DNA (ctDNA) samples and three germline DNA samples over the life history of 3 patients with triple-negative breast cancer (TNBC), 2 of whom had germline pathogenic BRCA1 mutation, to unravel tumor evolution. Tumor tissue from all timepoints and germline DNA was subjected to whole-exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived somatic mutation panel, and SNP arrays for copy-number variation (CNV), while whole transcriptome sequencing (RNA-seq) was performed only on somatic tumor. There was enrichment of homologous recombination deficiency signature in all tumors and widespread CNV, which remained largely stable over time. Somatic tumor mutation numbers varied between patients and within each patient (range: 70–216, one outlier). There was minimal mutational overlap between patients with TP53 being the sole commonly mutated gene, but there was substantial overlap in sequential samples in each patient. Each patient's tumor contained a founding (“stem”) clone at diagnosis, which persisted over time, from which all other clones (“subclone”) were derived (“branching evolution”), which contained mutations in well-characterized cancer-related genes like PDGFRB, ARID2, TP53 (Patient_02), TP53, BRAF, BRIP1, CSF3R (Patient_04), and TP53, APC, EZH2 (Patient_07). Including stem and subclones, tumors from all patients were polyclonal at diagnosis and during disease progression. ctDNA recapitulated most tissue-derived stem clonal and subclonal mutations while detecting some additional subclonal mutations. RNA-seq revealed a stable basal-like pattern, with most highly expressed variants belonging to stem clone. Significance: In germline BRCA1 mutated and BRCA wild-type patients, TNBC shows a branching evolutionary pattern of mutations with a single founding clone, are polyclonal throughout their disease course, and have widespread copy-number aberrations. This evolutionary pattern may be associated with treatment resistance or sensitivity and could be therapeutically exploited.

1 April 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
MSMinit Shah
Minit Shah
SRSushmita Rath
Sushmita Rath
SGSeema Gulia
Seema Gulia
PBPrabhat Bhargava
Prabhat Bhargava
ASAnbarasan Sekar
Anbarasan Sekar
SGSudeep Gupta
Sudeep Gupta
PURPOSE: There are scant data on patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with neoadjuvant therapy (NAT) in real-world settings with limited access to HER2-targeted therapy. METHODS: This was a retrospective analysis of patients with nonmetastatic, HER2-positive breast cancer treated with NAT between January 2014 and December 2018 to determine factors affecting pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS). RESULTS: The cohort comprised 1,004 patients with a median age of 47 years, 533 (53.1%) with clinical T3/T4 tumors, 466 (46.4%) with clinical N2/3 status, and 527 (52.5%) with hormone receptor–positive disease. Trastuzumab was given to 528 (52.6%) patients in the neoadjuvant setting and 711 (70.8%) patients in neoadjuvant and/or postoperative settings. pCR was achieved in 226 (22.5%) patients; the 5-year EFS in the whole cohort, pCR group, and no-pCR group was 63.5% (95% CI, 60.36 to 66.63), 86.1% (95% CI, 81.59 to 90.60), and 57% ([95% CI, 53.47 to 60.52]; P < .001), respectively. In multivariable analysis in the full cohort, smaller tumor size (cT1/T2 v cT3/T4), higher grade (III v II), hormone receptor–negative status, and use of neoadjuvant HER2-targeted therapy were significantly associated with higher pCR, and smaller tumor size (cT1/T2 v cT3/T4), lower node involvement (cN0/N1 v cN2/N3), achievement of pCR, and receiving trastuzumab were significantly associated with higher EFS and OS. CONCLUSION: In a setting with constrained access to HER2-targeted therapy, lower clinical tumor burden and receiving trastuzumab were significantly associated with increased pCR and survival in patients with HER2-positive breast cancer treated with NAT. Efforts should be made to enhance early diagnosis and access to HER2-targeted therapy worldwide.

14 February 2024
Verified
Other
Open access
NGNilesh Gardi
Nilesh Gardi
RCRohan Chaubal
Rohan Chaubal
PPPallavi Parab
Pallavi Parab
SPSunil Pachakar
Sunil Pachakar
SKSuyash Kulkarni
Suyash Kulkarni
SGSudeep Gupta
Sudeep Gupta
This table shows the genes in the germline sequencing panel for the targetted germline mutation assay.

14 February 2024
Verified
Other
Open access
NGNilesh Gardi
Nilesh Gardi
RCRohan Chaubal
Rohan Chaubal
PPPallavi Parab
Pallavi Parab
SPSunil Pachakar
Sunil Pachakar
SKSuyash Kulkarni
Suyash Kulkarni
SGSudeep Gupta
Sudeep Gupta
Graphical representation of clonal evolution observed in sequentially collected samples over time in 3 patients with TNBC. Timepoints are depicted on the X-axis and Cellular Prevalence (Clonal Prevalence) is shown on the Y-axis. Different colors in each patient represent various clones and their changing dynamics over time. Clonal phylogeny for each patient is shown on the left side of main figure. A, Patient_02. B, Patient_04. C, Patient_07.

14 February 2024
Verified
Other
Open access
NGNilesh Gardi
Nilesh Gardi
RCRohan Chaubal
Rohan Chaubal
PPPallavi Parab
Pallavi Parab
SPSunil Pachakar
Sunil Pachakar
SKSuyash Kulkarni
Suyash Kulkarni
SGSudeep Gupta
Sudeep Gupta
Graphical representation of clonal evolution observed in sequentially collected samples over time in 3 patients with TNBC. Timepoints are depicted on the X-axis and Cellular Prevalence (Clonal Prevalence) is shown on the Y-axis. Different colors in each patient represent various clones and their changing dynamics over time. Clonal phylogeny for each patient is shown on the left side of main figure. A, Patient_02. B, Patient_04. C, Patient_07.